First New Class of Pain Medicine in Decades Comes with A 14-Day Limit

A new prescription painkiller offers patients something doctors have sought for years: pain relief without an opioid and without the same concerns about addiction.

But there is an important limitation.

Suzetrigine, sold under the brand name Journavx, is approved only for short-term pain, and treatment is limited to 14 days.

The U.S. Food and Drug Administration approved the medication in January 2025, making it the first new class of pain medicine approved in more than two decades. Unlike medications such as hydrocodone and oxycodone, suzetrigine is not an opioid or a controlled substance and is not expected to cause dependence.

That difference comes from where and how the medication works.

Opioids act inside the brain, changing how the brain responds after a pain signal arrives. Suzetrigine acts earlier in the process. It blocks a sodium channel in peripheral nerves, interfering with the pain signal before it reaches the brain.

Because the drug does not act on the brain’s opioid receptors, it does not produce the euphoria associated with opioid misuse and addiction.

That doesn’t mean it is necessarily a more powerful painkiller.

Clinical trials involving patients recovering from abdominal surgery and bunion surgery found that suzetrigine provided better pain relief than a placebo. Its effectiveness was roughly comparable to hydrocodone combined with acetaminophen, rather than significantly better.

Where the new medication may have an advantage is in avoiding some of the problems associated with opioids.

In one of the trials, about 20% of patients taking suzetrigine reported nausea or vomiting, compared with 33% of patients receiving the opioid medication.

Why Only 14 Days?

The two-week limit may sound like a warning about the drug’s safety, but that isn’t the reason for it.

Suzetrigine is approved for treating moderate to severe acute pain in adults, and the FDA label says use for more than 14 days has not been studied.

In other words, the limit reflects the available evidence rather than a finding that the medication becomes dangerous on Day 15.

Reported side effects in studies were generally mild. Itching occurred in about 2% of patients. Muscle spasms, rash, and an increase in a muscle-related enzyme were each reported in roughly 1% of patients.

The studies found no serious adverse reactions attributable to the medication.

The distinction between what researchers know and what remains unknown is particularly important for people living with chronic pain.

Chronic Pain Remains An Open Question

The approval doesn’t mean suzetrigine is a new long-term treatment for arthritis, chronic back pain, or other conditions that can last for months or years.

Those uses require additional research.

A mid-stage study involving nerve-related lower back pain produced results that only narrowly separated the drug from placebo.

Researchers continue to investigate whether the medication could help with longer-lasting pain conditions. A late-stage clinical trial involving about 1,100 patients with diabetic nerve pain is underway.

Those studies could eventually provide evidence for broader uses, but for now Journavx remains a medication for acute pain.

That makes its immediate role more likely to involve situations such as pain following surgery or an injury, where patients may otherwise receive an opioid for a limited period.

The drug’s significance is therefore less about providing stronger pain relief and more about giving doctors and patients another option.

For decades, physicians treating moderate to severe acute pain have often had to weigh the effectiveness of opioids against their potential for misuse, dependence, and addiction.

Suzetrigine approaches the problem differently by interrupting pain signals outside the brain.

That mechanism could become particularly important if future research shows that the same approach works safely for other types of pain.

Cost Could Be Another Barrier

Price could also determine how many patients actually receive the medication.

Without insurance, an estimated 30-tablet supply — roughly one full treatment course — can cost between $475 and $675.

Insurance coverage can vary.

For patients whose insurance doesn’t cover Journavx, a short course of pain medication can cost several hundred dollars, making the newer option hard to afford.

That could leave some patients and their doctors choosing among the same medications they used before Journavx became available.

For now, suzetrigine represents an important change in pain medicine, but not a replacement for every other pain treatment.

It isn’t stronger than opioids based on the available surgical trials; it hasn’t been established for long-term chronic pain, and cost and insurance coverage may limit access.

What it does provide is something medicine hasn’t seen in decades: a new way of treating moderate to severe acute pain without relying on opioids.

And while its current window is only 14 days, ongoing research will help determine whether that window — and the drug’s role in pain treatment — eventually becomes larger.